市場調查報告書
商品編碼
1271366
氣管插管市場規模、市場份額、應用分析、區域展望、增長趨勢、主要參與者、競爭戰略、預測,2023-2031 年Endotracheal Tubes Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031 |
在 2023 年至 2031 年的預測期內,全球氣管導管市場預計將以 6.5% 的複合年增長率增長。 心血管疾病、癌症和其他呼吸系統疾病等慢性病的增加增加了需要氣管插管的外科手術的數量。 根據世界衛生組織 2019 年的一份報告,呼吸系統疾病是全球死亡的主要原因,每年約有 400 萬人死亡。 因此,預計該市場在未來幾年將出現有利可圖的增長。
手術次數的增加推動了對氣管插管的需求。 根據《全球外科和麻醉統計》報告,每年大約進行 31.3 億次外科手術。 氣管插管技術的進步不僅降低了與插管相關的感染風險,還提高了產品安全性。 使用氣管導管或呼吸機超過 48 小時的患者最有可能發生呼吸機相關性肺炎 (VAP),並且這種疾病呈上升趨勢。 因此,許多市場進入者正在努力開發具有抗菌和抗凝塗層的產品,以減少 VAP。 例如,據報導 Medtronic Shiley Evac 氣管插管可將 VAP 降低 50.0%。 因此,隨著 VAP 發病率的增加,對塗層氣管插管的需求也在增加,從而刺激了市場的擴張。 因此,氣管插管技術的進步和更容易患許多慢性病的人口老齡化預計將在預測期內增加市場增長機會。
由於呼吸困難是傳染病的明顯徵兆,COVID-19 的出現顯著增加了對氣管插管的需求,推動了市場擴張。 對於 COVID 患者的呼吸衰竭,美國支氣管學會建議採用開放式外科氣管切開術 (OST) 或經皮擴張氣管切開術。 大流行使緊急產品批准成為可能。 美國生物技術公司 N8 的 CeraShield 氣管導管已獲得加拿大衛生部的緊急使用授權,用於機械通氣的 COVID-19 患者。 該公司的專利防污塗層旨在防止致命的細菌感染。 氣管插管和機械通氣可幫助 COVID-19 患者在免疫系統對抗病毒的同時呼吸並維持生命。 這將增加您成功對抗病毒的機會。 這種情況有望刺激市場擴張。
為防止醫院感染,製造商正在努力開發創新的氣管插管。 例如,2 月,N8 Medical, LLC 向 FDA 提交了 IDE(調查設備豁免),以進行 CeraShield 氣管內插管 (ETT) 的首次人體臨床試驗。 該臨床試驗的目的是評估 CeraShield 氣管插管 (ETT) 的安全性和有效性。
醫院因機械通氣引起的肺炎等感染正在推動插管市場的增長。 重症監護病房因手術並發症而導致患者死亡的風險最高,其中之一是院內感染等繼發過程引起的病情加重。
到 2022 年,常規氣管插管細分市場佔據主導地位,收入份額最大,達到 32.5%,這是由於與呼吸系統疾病患病率上升相關的外科手術增加。 隨著 VAP 發病率的增加,預計未來對氣管插管的需求也會增加。 因此,預計該行業在預測期內將呈現有利可圖的增長。 市場按產品類型分為常規氣管插管、強化氣管插管、高性能氣管插管和雙腔氣管插管。
到 2022 年,氣管造口術細分市場的收入份額最大,達到 65%。 根據路線類型,市場分為氣管內和經鼻氣管。 氣管插管以其適用性廣、利用率高、舒適度高等優點佔據了最大的市場份額。 氣管插管用於保護所有手術患者的氣道。 也用於重傷患者和合併多器官疾病的危重患者。
到 2022 年,急症護理領域佔市場的最大收入份額,達到 55%。 市場進一步細分為急性護理、治療和其他應用。 這一部分的最大份額可歸因於心臟驟停、呼吸、氣道阻塞和通風不足等緊急情況發生率的上升、交通事故事件的增加以及發展中國家可支配收入的增加。 然而,預計治療領域在預測期內將經歷更大的增長。 在預測期內,這一領域的增長預計將主要受到外科手術增加、慢性呼吸道疾病流行和人口老齡化的推動。
2022 年,由於全球住院趨勢,醫院部門的收入份額最大,超過 35%。 該市場按最終用戶細分為醫院、門診手術中心、診所等。 此外,醫院醫生和護理人員的高度認可也促進了這一領域市場份額的增長。 預計診所市場將在預測期內實現最大增長。 慢性呼吸系統疾病的增加、診所福利意識的提高以及公平的報銷政策推動了這一細分市場的擴張。 然而,由於北美和亞太地區的中心擴張,預計門診手術中心在預測期內也將出現顯著增長。
由於先進的醫療保健系統和慢性病患病率上升,北美在 2022 年主導了氣管插管市場,佔全球收入的 35% 以上。 該地區也有重要的市場進入者,這有助於擴大市場。 Teleflex Incorporated、Medline Industries 和 Medtronic 是該地區最著名的三家公司。
快速採用先進的醫療保健技術來增強醫療保健已成為影響市場競爭力的關鍵因素。 除了推出新產品外,大公司還經常進行併購以保持市場份額並使產品組合多樣化。 Medtronic Plc、Teleflex Inc、ConvaTec Inc、Smiths Medical、Neurovision Medical Products、Intersurgical Inc、Royax、Novo Klinik-Service GmbH、Avanos Medical, Inc、Bactiguard、N8 Medical LLC 和其他知名企業正在引領氣管插管市場。的主要參與者
The global endotracheal tube market is projected to expand at a CAGR of 6.5% during the forecast period of 2023 to 2031. Increasing incidences of chronic diseases such as cardiovascular disease, cancer, and other respiratory diseases have led to an increase in the number of surgical procedures requiring endotracheal tubes. According to the 2019 World Health Organization report, respiratory diseases are the leading cause of death worldwide, accounting for approximately 4.0 million deaths annually. Consequently, the market is anticipated to exhibit lucrative growth over the coming years.
The demand for endotracheal tubes has been fuelled by an increase in the number of surgeries. According to the report Global Surgery and Anaesthesia Statistics, approximately 313,0 million surgical procedures are performed annually. In addition to reducing the risk of infection associated with tubes, technological advances in endotracheal intubation have enhanced product safety. Patients who have been on an endotracheal tube or mechanical ventilator for more than 48 hours are the most likely to develop Ventilator-Associated Pneumonia (VAP), a condition that has been on the rise. Thus, numerous market participants are developing products with antimicrobial and anticoagulant coatings that can reduce VAP. For instance, it has been reported that Medtronic Shiley Evac endotracheal tubes reduce VAP by 50.0%. Consequently, as the incidence of VAP rises, so does the demand for coated endotracheal tubes, fueling the market's expansion. Consequently, technological advancements in endotracheal tubes and an aging population that is increasingly susceptible to numerous chronic diseases will increase the market's growth opportunities during the forecast period.
As breathing difficulty is a clear indication of infection, the emergence of COVID-19 has greatly increased the demand for endotracheal tubes, which has fueled the market expansion. In cases of respiratory failure in COVID patients, the American Association for Bronchology and Interventional Pulmonology suggests Open Surgical Tracheostomy (OST) or percutaneous dilatational tracheostomy. This pandemic made emergency product approvals possible. N8, a U.S.-based biotechnology company, obtained emergency use authorization from Health Canada for its CeraSheild Endotracheal Tubes in COVID-19 patients receiving mechanical ventilation. The anti-fouling coating on the company's patented product is designed to prevent deadly bacterial infections. Endotracheal intubation and ventilation support a COVID-19 patient's breathing so that the patient can survive while the immune system battles the virus. This increases the likelihood of successfully combating the virus. Such scenarios are anticipated to stimulate market expansion
Increased launches and approvals of advanced and efficient endotracheal tubes by key players are anticipated to propel the endotracheal tube market over the coming years. In November 2016, Bactiguard introduced the BIP Endotracheal Tube Evac to prevent ventilator-associated pneumonia in patients (VAP). To prevent ventilator-associated pneumonia (VAP) infections, the innovative BIP Endotracheal Tube Evac has subglottic secretion drainage and a Bactiguard coating.
In order to prevent hospital-acquired infections, manufacturers are emphasizing the creation of innovative endotracheal tubes. For instance, in February, N8 Medical, LLC submitted to the Food and Drug Administration (FDA) the Investigational Device Exemption (IDE) for the first-in-human clinical study of its CeraShield Endotracheal Tube (ETT). The purpose of the clinical trial is to assess the safety and effectiveness of the CeraShield Endotracheal Tube (ETT).
Nonetheless, the increasing prevalence of hospital-acquired infections, such as ventilator-associated pneumonia, is anticipated to restrain the growth of the endotracheal tube market during the forecast period. According to the National Center for Biotechnology Information, the incidence of ventilator-associated pneumonia (VAP) in the United States ranged from 2 to 16 episodes per 1,000 ventilator days in November 2017.
Hospitals that have acquired infections such as pneumonia associated with mechanical ventilation are driving the growth of the intubation tube market. In intensive care units, patients are at the highest risk of death due to procedure complications or other causes, one of which is a critical illness caused by secondary processes, such as nosocomial infection.
Pneumonia, which affects 27% of critically ill patients, is the second most common nosocomial infection, after urinary tract infections. Nearly 86% of nosocomial pneumonia is caused by pneumonia associated with mechanical ventilation.
Mortality associated with ventilator-associated pneumonia has been estimated to range between 0% and 50%. When it comes to assessing attributable mortality, different studies have yielded divergent results due to the diversity of the populations examined.
In 2022, the segment of regular endotracheal tubes dominated the market and held the largest revenue share of 32.5% due to the increasing number of surgical procedures as a result of the rising prevalence of respiratory diseases. Also, as the incidence of VAP rises, the demand for endotracheal tubes is anticipated to increase in the future. As a result, the segment is anticipated to exhibit lucrative growth over the forecast period. The market has been divided into regular endotracheal tubes, reinforced endotracheal tubes, performed endotracheal tubes, and double-lumen endotracheal tubes based on the type of product.
However, the reinforced endotracheal tube segment is expected to grow at a faster rate over the forecast period due to its increasing use during surgery and recent technological advancements in endotracheal tubes. In addition, the increasing incidence of road accidents and trauma injuries will contribute to the segment's growth over the forecast period.
In 2022, the orotracheal segment held the largest revenue share of 65% of the market. The market has been classified as orotracheal and nasotracheal based on route type. Orotracheal has the largest market share due to its broad applicability, increased utilization, and comfort. Orotracheal intubation is utilized to control the airway of any surgical patient. It is also used for patients with severe injuries or multisystem diseases who are critically ill.
Orotracheal incubation is commonly used in emergency situations such as respiratory or cardiac arrest, inadequate oxygenation or ventilation, failure to protect the airway from aspiration, and existing or anticipated airway obstruction. Due to this, the demand for orotracheal tubes has increased over the past few years, and the segment is expected to grow at a healthy rate over the forecast period. Additionally, the aforementioned factors will increase demand for orotracheal intubation over the forecast period. Due to the rising prevalence of respiratory disease, it is anticipated that the nasotracheal segment will experience the highest CAGR of 5.6% during the forecast period.
In 2022, the emergency treatment segment held the largest revenue share of 55% of the market. The market is further segmented by application into emergency treatment, therapy, and others. The largest share of this segment can be attributed to the rising incidence of emergency conditions such as cardiac arrest and respiratory, airway obstruction and inadequate ventilation, rising cases of road accidents, and growing disposable income in developing nations. Nonetheless, the therapy segment is anticipated to experience greater growth during the forecast period. During the forecast period, the segment's growth will be driven primarily by the increasing volume of surgical procedures, the prevalence of chronic respiratory diseases, and the aging population.
In 2022, the hospital's segment held the largest revenue share at over 35% due to the global trend toward hospitalization. The market has been segmented by end-use into hospitals, ambulatory surgical centers, clinics, and others. In addition, high awareness among hospital physicians and nursing staff contributes to the segment's increasing market share. The clinics market segment is anticipated to experience the greatest growth during the forecast period. The increasing prevalence of chronic respiratory diseases, rising awareness of the benefits of clinics, and equitable reimbursement policies will drive the expansion of this market segment. However, ambulatory surgical centers are also anticipated to experience significant growth over the forecast period due to the expansion of centers in North America and Asia-Pacific.
Due to its advanced healthcare system and rising prevalence of chronic diseases, North America dominated the endotracheal tubes market in 2022, accounting for more than 35% of the global revenue. In addition, the presence of significant market participants in the region contributed to market expansion. Teleflex Incorporated, Medline Industries, and Medtronic are three of the region's most prominent companies.
In 2022, the United States contributed over 30% of the global Intubation Tube Market revenue. The increase in tracheal diseases, such as tracheal stenosis, bronchial tumors, and tracheobronchomalacia, has increased the country's demand for intubation tubes. The National Cancer Institute estimates that there will be 236 740 new cases of lung and bronchial cancer in the United States in 2022, which represents 12.3% of all new cancer cases. This will bring the death toll for this disorder to 130,180, or 21.4% of all cancer-related deaths in the country.
Asia-Pacific is anticipated to experience the market's fastest growth over the forecast period. The increasing geriatric population with respiratory disease, rising prevalence of ventilator-associated pneumonia, and rising number of surgeries due to chronic cardiovascular disease are expected to increase regional demand for endotracheal tubes.
The rapid adoption of advanced healthcare technology for enhanced healthcare is a crucial factor influencing the market's competitiveness. In addition to new product launches, major players frequently engage in mergers and acquisitions in order to retain market share and diversify their product portfolios. Medtronic Plc, Teleflex Inc., ConvaTec Inc., Smiths Medical, Neurovision Medical Products, Intersurgical Inc., Royax, Novo Klinik-Service GmbH, Avanos Medical, Inc., Bactiguard, N8 Medical LLC and Other Notable Players are some of the key players in the endotracheal tube market.
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Endotracheal Tubes market are as follows:
Micro and macro environment factors that are currently influencing the Endotracheal Tubes market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.